The Board of AstraZeneca plc (NASDAQ: AZN) is recommending to shareholders a Harmonized Listing Structure for the company's ordinary shares across the London Stock Exchange (LSE), Nasdaq Stockholm (STO), and the New York Stock Exchange (NYSE). It requires upgrading AstraZeneca's existing U.S. equity listing by way of a direct listing of AstraZeneca ordinary shares on the NYSE, replacing the existing U.S. listing of AstraZeneca ADRs on Nasdaq, the company said in a press release on Monday. Following the i ...

Sir Pascal Soriot, AstraZeneca’s CEO, has described the pharmaceuticals giant as a ‘very American company’ - Umit Bektas/Reuters AstraZeneca has announced plans to list shares on the New York Stock Exchange, stoking fears that Britain’s biggest drugmaker could quit London. In a shake-up announced on Monday, the FTSE pharmaceuticals giant said it would upgrade its US listing to ensure it is equally as important in New York as it is on the London Stock Exchange. Bosses said the move would make it easier f ...

在近日召开的"2025阿斯利康中国研发日"期间，阿斯利康全球执行副总裁、生物制药研发负责人贝旭鸿 接受记者采访时表示，阿斯利康今年初宣布在北京投资25亿美元，其中包括在北京建立第六个全球战略 研发中心，并计划建立一个先进的人工智能（AI）和数据科学实验室。主要原因包括：中国已成为全 球创新药物枢纽，且在整个过程中，药物研发和创新势头都非常良好。同时，全球范围内，由中国研发 的药物数量也出现了翻倍的增长，约三分之一的全球授权交易是与中国生物制药企业达成的。 "过去两年，阿斯利康已与14家中国生物技术公司（biotech）签订了15项授权许可交易。"贝旭鸿举例 称，两年前，阿斯利康与诚益生物签订了战略合作协议。诚益生物的候选分子药物AZD5004，是一个 小分子药物，阿斯利康希望通过自身研发和生产平台，能够尽快地开发这款创新的小分子药物。"这款 药物的研发进展良好，目前全球正在进行2B期的临床试验，预计会在今年年底或2026年年初进行公 布。"贝旭鸿说。 贝旭鸿表示："近年来，中国凭借丰富的临床研究资源与不断提升的创新能力，正逐渐成为全球基础研 究和临床开发的关键枢纽，在药物研发中发挥着越来越大的价值。期待未来在 ...

AstraZeneca announced plans to change how it lists shares in the United States by moving from American depositary receipts (ADRs) on Nasdaq to a direct listing of its ordinary shares on the New York Stock Exchange. ...

Key TakeawaysBrent Crude is struggling to maintain the $70 per barrel mark, with forecasts suggesting further declines into 2026 due to a persistent supply glut and weakened demand.The USD/JPY currency pair extended losses, dropping 0.6% to 148.61, as the Japanese Yen gained amidst divergent economic performances between the US and Japan.Security services firm Verisure is targeting a substantial valuation of up to €13.9 billion in its anticipated Stockholm IPO.AstraZeneca (AZN) announced plans for a direct ...

智通财经APP获悉，阿斯利康公司(AZN.US)计划在纽约证券交易所上市股票，以吸引更多投资者，但 将继续保留其在伦敦的股票交易业务及英国总部。该公司在周一发布的声明中表示，此次在美国上市的 股票将取代其现有的美国存托凭证(American Depository Receipts)。 首席执行官帕斯卡尔・索里奥特(Pascal Soriot)长期以来对英国的监管体系不满，并担忧英国在竞争力方 面正落后于美国和中国。制药企业对英国政府推动本国生命科学产业发展的举措日益感到失望，从临床 试验数量到新药报销政策，企业对多个领域的问题均提出了异议。 此前有报道称该公司已暂停了其在本土市场的重大投资。这家英国最大的上市公司成为最新一家缩减在 该国业务的制药企业。该公司发言人上周五晚些时候表示，其已暂停了在剑桥研发中心进行的 2 亿英镑 (约合 2.7212 亿美元)的投资计划，此举对英国政府来说是一个打击。 此前在 7 月，就有市场猜测这家制药企业可能将上市地点迁至美国，如今阿斯利康正式发布了上述声 明。美国拥有全球流动性最高的公开市场，同时聚集了数量最多的创新生物制药企业与投资者，阿斯利 康表示，希望能够进入这一市场 ...

阿斯利康9月29日发布声明称，公司计划协调其股票上市结构，在伦敦证券交易所、斯德哥尔摩证券交 易所和纽约证券交易所为公司普通股上市。这将升级阿斯利康现有的美国股票上市体系，取代现有的美 国存托凭证（ADR）在纳斯达克上市。 阿斯利康表示，公司总部将留在英国。 来源：智通财经 ...

AstraZeneca to List Shares Directly on New York Stock Exchange https://t.co/WNnlQy1BnT ...

(Reuters) -AstraZeneca (AZN) plans to directly list its shares on the New York Stock Exchange, instead of its current depositary receipts structure, to attract more global investors, the drugmaker said on Monday, but will remain listed and headquartered in London. The move will be of some relief to UK investors after media reports suggested the Anglo-Swedish drugmaker - London's most valuable company - was considering ditching its British listing in favour of the U.S. That had raised worries about the shr ...

AstraZeneca said on Monday that it will now directly list its shares on the New York Stock Exchange, instead of the current depository shares, adding that it will continue to be listed and headquarter... ...